Optimal voriconazole dosing regimens for obese patients:A systematic review
10.13699/j.cnki.1001-6821.2016.05.024
- VernacularTitle:肥胖人群伏立康唑给药方案的系统评价
- Author:
Ken CHEN
1
;
Meng-Jia GE
;
Suo-Di ZHAI
Author Information
1. 北京大学 第三医院 药剂科
- Keywords:
voriconazole;
obesity;
dosing regimens;
actual body weight;
ideal body weight;
adjusted body weight
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(5):459-461
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the optimal voriconazole dosing regimens for obese patients.Methods PubMed, EmBase, the Cochrane Library, Clinicaltriasl.gov and three Chinese databases ( CNKI, CBM, and Wan-Fang ) were searched through March 2015.Clinical trials or observational studies comparing the clinical and pharmacokinetic outcomes of different dosing regimens in obese patients or healthy subjects were included.Results Three cohort studies involving 237 subjects were included in the review.There were no statistical difference among actual body weight ( ABW) , ideal body weight ( IBW) , adjusted body weight ( AdjBW) and normal body weight ( NBW) groups on rates of hepatotoxicity and neuro-toxicity.No studies reported clinical response of treatment.Attainment of target concentration in AdjBW group was significantly higher than ABW and NBW group , respectively.Random plasma concentration in ABW group was significantly higher than NBW group when using intravenous administration (Median 6.4 vs 2.8μg· mL-1 ).Trough concentration in ABW group was significantly higher than NBW ( MD=2.70μg· mL-1 ) , IBW ( MD=2.25μg· mL-1 ) and AdjBW ( MD =2.90 μg · mL-1 ) groups , respectively.Conclusion Voriconazole AdjBW and IBW dosing regimens are recommended for obese patients.Drug monitoring may be necessary for obese patients to ensure the safety of voriconazole.
